Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio

Fineline Cube Apr 20, 2026
Company Deals

AbbVie Partners with Santen China for Exclusive Distribution of Five Glaucoma Franchise Products

Fineline Cube Apr 17, 2026
Company Deals

Annoroad Gene Technology Files for Hong Kong IPO to Capitalize on Integrated Molecular Diagnostics Platform

Fineline Cube Apr 17, 2026
Company Deals

Mabwell Bioscience Expands Southeast Asia Reach with Malaysian Licensing Deal for Denosumab Biosimilars Rexeva and Denosu

Fineline Cube Apr 17, 2026
Company Deals Digital

Tigermed and Alibaba Cloud Forge Alliance to Build AI-Powered Ecosystem for Intelligent Clinical Trials

Fineline Cube Apr 17, 2026
Policy / Regulatory

China’s NMPA Proposes New Quality Management Standards for Drug Retail Chains – Mandating Unified Systems Across Headquarters, Distribution Centers, and Stores

Fineline Cube Apr 20, 2026
Company Drug

Xuanzhu Biopharmaceutical Reports Landmark Phase III DIAMOND-2 Results for Xuanfeining (Dirozalkib) in ALK-Positive NSCLC – 31.3-Month PFS Doubles Crizotinib Standard at AACR 2026

Fineline Cube Apr 20, 2026
Company Drug

Sino Biopharmaceutical Reports 55% Response Rate for PD-1/VEGF Bispecific LM-299/MK-2010 in NSCLC at AACR 2026

Fineline Cube Apr 20, 2026
Company Medical Device

MicroPort CardioFlow Medtech’s AnchorMan System Receives NMPA Approval as First Semi-Closed LAA Occluder in China

Fineline Cube Jan 8, 2024

MicroPort Scientific Corp (HKG: 0853), a leading medical device company based in China, has announced...

Company Deals

Ningbo Linstant Polymer Materials Secures Over USD 14 Million in Series B Financing to Boost Production and Global Reach

Fineline Cube Jan 8, 2024

Ningbo Linstant Polymer Materials Co., Ltd, a Chinese manufacturer specializing in polymer accessories for medical...

Company Deals

Lion TCR Partners with MaxCyte to Develop mRNA-Based TCR-T Therapies for Solid Tumors and Viral Diseases

Fineline Cube Jan 8, 2024

Lion TCR, a Singapore-based clinical-stage biotechnology company with backing from Chinese investors, has entered into...

Company Deals

OnCusp Therapeutics Secures Oversubscribed USD 100 Million Series A Financing for CDH6-Targeting ADC

Fineline Cube Jan 8, 2024

OnCusp Therapeutics, a U.S.-based biopharmaceutical company, has closed an oversubscribed Series A financing round, raising...

Company Deals

Merck In-Licenses Inspirna’s Ompenaclid for Advanced Colorectal Cancer, Eyes Market Potential

Fineline Cube Jan 5, 2024

Germany-based Merck (NYSE: MRK) has in-licensed the potential first-in-class candidate ompenaclid from U.S. firm Inspirna,...

Company Deals

Boehringer Ingelheim Teams Up with 3T Biosciences for Next-Gen T-Cell Cancer Therapies

Fineline Cube Jan 5, 2024

German pharmaceutical leader Boehringer Ingelheim (BI) has entered into a new agreement with U.S.-based 3T...

Company Deals

Novo Nordisk Expands U.S. Ties, Collaborates with Flagship Pioneering on Cardiometabolic Advances

Fineline Cube Jan 5, 2024

Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) is advancing its U.S. partnerships by joining forces...

Company Deals

Menarini’s Stemline Signs $500M+ License with Insilico for Cancer Drug Candidate

Fineline Cube Jan 5, 2024

Italy’s Menarini Group, through its subsidiary Stemline Therapeutics, has entered an exclusive license agreement with...

Company Drug

Genrix Bio Seeks China Approval for New Xeligekimab Use in Axial Spondyloarthritis

Fineline Cube Jan 5, 2024

Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA: 688443), a biopharmaceutical company based in China, has submitted...

Policy / Regulatory

Shanghai Pharmaceuticals’ Subsidiary Reprimanded Again for Monopolisitic Pricing of Polymyxin B Sulfate

Fineline Cube Jan 5, 2024

The Shanghai Administration for Market Regulation (AMR) bureau has once again reprimanded SHP No.1 Biomedical...

Company Drug

Akeso Biopharma Submits New Indication Application for Cadonilimab in Gastric Cancer Treatment

Fineline Cube Jan 5, 2024

Akeso Biopharma (HKG: 9926), a leading biopharmaceutical company based in China, has announced the submission...

Company Drug

JW Therapeutics Secures NMPA Review for CAR-T Therapy in Mantle Cell Lymphoma

Fineline Cube Jan 5, 2024

JW Therapeutics (HKG: 2126), a Chinese biopharmaceutical company, has announced that it has submitted an...

Hospital Policy / Regulatory

China’s Ministry of Education Launches Professional Guidelines for Healthcare Talent Training

Fineline Cube Jan 5, 2024

The Ministry of Education (MoE) in China has issued a Notice outlining the “Professional Guidelines...

Company Drug

Jiangsu Hengrui Pharmaceuticals Advances Novel Cancer Therapies with NMPA Clinical Trial Approval

Fineline Cube Jan 5, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received approval from the National Medical Products...

Company Deals

Suzhou Elite Analytical Instruments Secures Over $14 Million in Initial Funding Round

Fineline Cube Jan 5, 2024

Suzhou Elite Analytical Instruments Co., Ltd, a leading specialist in liquid chromatography based in China,...

Company Drug

Jiangsu Vcare PharmaTech Submits NDA to US FDA for Vicagrel, a P2Y12 Receptor Antagonist

Fineline Cube Jan 5, 2024

Jiangsu Vcare PharmaTech Co., Ltd, a Chinese pharmaceutical company, has submitted a New Drug Application...

Company Deals

Allorion Therapeutics and Avenzo Seal Deal for Global Rights to CDK2 Inhibitor

Fineline Cube Jan 5, 2024

China-based Allorion Therapeutics has entered into a licensing agreement with Avenzo Therapeutics Inc., granting the...

Company Drug

BMS’s Sotyktu, First TYK2 Inhibitor, Hits Chinese Market

Fineline Cube Jan 5, 2024

US pharmaceutical giant Bristol Myers Squibb (BMS, NYSE: BMY) has announced the market launch of...

Legal / IP

China’s National People’s Congress Approves Stricter Punishments for Sector-Specific Bribery

Fineline Cube Jan 4, 2024

The 7th meeting of the 14th National People’s Congress Standing Committee has passed the latest...

Company Deals Legal / IP

Daiichi Sankyo and Esperion Therapeutics Amend Collaboration on Antilipidemic Drugs

Fineline Cube Jan 4, 2024

Daiichi Sankyo (TYO: 4568)’s European subsidiary, a Japanese pharmaceutical company, has entered into a collaboration...

Posts pagination

1 … 407 408 409 … 653

Recent updates

  • China’s NMPA Proposes New Quality Management Standards for Drug Retail Chains – Mandating Unified Systems Across Headquarters, Distribution Centers, and Stores
  • Xuanzhu Biopharmaceutical Reports Landmark Phase III DIAMOND-2 Results for Xuanfeining (Dirozalkib) in ALK-Positive NSCLC – 31.3-Month PFS Doubles Crizotinib Standard at AACR 2026
  • Sino Biopharmaceutical Reports 55% Response Rate for PD-1/VEGF Bispecific LM-299/MK-2010 in NSCLC at AACR 2026
  • Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio
  • AbbVie Partners with Santen China for Exclusive Distribution of Five Glaucoma Franchise Products
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

China’s NMPA Proposes New Quality Management Standards for Drug Retail Chains – Mandating Unified Systems Across Headquarters, Distribution Centers, and Stores

Company Drug

Xuanzhu Biopharmaceutical Reports Landmark Phase III DIAMOND-2 Results for Xuanfeining (Dirozalkib) in ALK-Positive NSCLC – 31.3-Month PFS Doubles Crizotinib Standard at AACR 2026

Company Drug

Sino Biopharmaceutical Reports 55% Response Rate for PD-1/VEGF Bispecific LM-299/MK-2010 in NSCLC at AACR 2026

Company Deals

Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.